A Study to Evaluate ABP 206 Compared With OPDIVO ® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Conditions: Melanoma Interventions: Drug: ABP 206; Drug: Nivolumab Sponsors: Amgen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials